Nesclerosis multiple ejercicios fisioterapia pdf

Pacheco da costa 3 tratamiento fisioterapeutico en esclerosis multiple. It is a demyelinating disease of the central nervous system whose. The clinical course is usually characterized by severe. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. It is a demyelinating disease of the central nervous system whose evolution is unpredictable and its effects and symptoms are varied1,2. Recommendations for physical activity in patients with multiple. Multiple sclerosis ms is a chronic inflammatory and neurodegenerative disease characterized by focal areas of demyelinationaxonal damage known as plaques. Procedimiento fisioterapeutico en esclerosis multiple en fase aguda. Multiple sclerosis main anatomopatological observation is the immunological destruction of myelin1. Tratamiento fisioterapeutico en esclerosis multiple. The purpose of this paper is to revise the current concepts of multiple sclerosis ms on its diverse ways of manifestation, its. The diagnostic criteria currently used include clinical or paraclinical demonstration of the dissemination of these lesions in space and time, and the exclusion of alternative.

En una revision cochrane realizada por rietberg et al. Neurorrehabilitacion del paciente con esclerosis multiple. Multiple sclerosis is the major cause of neurological disability in young and middleaged adults. Toda persona con esclerosis multiple, em debe tomar en cuenta su nivel. The pattern of cognitive impairment is not uniform. Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and parkinsons disease. Esclerosis multiple avanzada, manifestaciones y tratamiento. Multiple sclerosis in bud stage presents as an inflammatory process that requires steroid treatment. However, the disco v e r y of new ways of diagnosis as the magnetic re sonance imaging mri and the new tre a t m e n t s such as interferon 1a and 1b have provided an im p o r tant change in pronostic and quality of life in these patients. It is the leading cause of disability in this group.

1250 963 593 1293 434 1515 347 303 1191 882 1087 1032 235 840 817 970 1080 530 499 166 1132 978 1426 237 70 635 547 714 1451 194